Akebia Therapeutics, Inc.
Here’s whether Akebia Therapeutics, Inc. (AKBA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 21 — oversold; weak 1-year return of -73.5%; 3-month momentum negative (-17.7%); rising volume on a downtrend (distribution, 1.49x avg). Currently 73.9% off its 52-week high. Score: -6/7.
AKBA is trading below its 200-day MA ($1.38) — a key warning sign the longer-term trend is under pressure. An RSI of 21.4 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -73.5% compares to +20.4% for SPY (trailed the market by 93.8%). The current 73.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.